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qTherapy – related leukemia (t-MN) is far from being a well known syndrome, but progress is being made.  It is a 
distinctive clinical syndrome in patients with preceding solid tumor or hematologic malignancies that were treated 
with cytotoxic procedures . Because there is an increasing number of cured patients at risk of developing  Therapy – 
Acute Myeloid Leukemia due to prior radio or chemotherapies, bigger efforts are made in order to gain further 
knowledge.  
 
q There is close association between distinct subtypes of t-MN and the  
       nature of previous treatment:  
  
 
 
 
 
 
 
q It gives us a unique chance to assess the effects of carcinogenesis and 
         mutagens in humans, and to analyse individual predisposing factors. 
 
 
As a literature review, information was extracted from 
several articles on scientific databases, searching for the 
following key-words: secondary malignancies, therapy-
related leukemia, topoisomerase II inhibitors. Other 
material was consulted in order to solve concept 
misunderstandings. For the written report, the most 
relevant information was selected.  
Introduction 
 
 
 
 
 
 
 
New treatments 
Effective anticancer treatments         increase in survival/overall cure rate        ↑ more cases of people with secondary leukemia due to previous treatments 
q Shortage of data from treatments to previous malignancies, together with few data from t-MN patients       needed to expand current knowledge  
q Prevention using less leukemogenic compounds when possibly, while implementing schedules with longer period and lower dosage 
q Individual susceptibility from differences in membrane transport, drug catabolism an inefficient DNA repair        study of polymorphisms involved  
q Emergence of new treatments could lead to a progressive disappearance of leukemogenic agents in protocols        gene therapy is a promising tool   
q Important to aware clinicians about the pros and cons of using topoisomerase II inhibitors 
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• MDS with chr. 7 and/or 5 loss/rearrangement/deletion 
• Latency from 3-7 years after cytotoxic exposure 
Alkylating 
agents 
• Balanced translocations involving MLL, AML1,  ...   
• Younger age, directly AML and shorter latency after exposure  
Topoisomerase 
II inhibitors 
The aim of this work is to understand what are therapy-
related leukemias, specially the role that topoisomerase 
II inhibitors have on them. In this line, find information 
about what these agents cause and if there are any 
alternative treatments in order to avoid their use.  
Methodology  
Objectives  
Figure 1: Risk factors for therapy-related leukemia 1  
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Figure 3. Treatment algorithm for the management of t-AML patients 3 
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q  Mechanism of action: Block the enzymatic reaction through religation and enzyme release, leaving DNA with a permanent strand break (=apoptosis). 
 Leukemogenic and antineoplastic effect           chromosomal breakages resolved by chromosomal translocation (leukemic transformation) 
q  Side effects: Onset of a wide spectrum of secondary malignancies due to topoisomerase II inhibitors administration (high potential to generate translocations) 
  Rarely preceded by t-MDS 
q  Clinical profile    Shorter  latency  (2-3y from 1st exposure) 
  Rapidly progressive leukemia 
 
q  Individual susceptibility factors:    
                                    Genetic polymorphisms in 
• Strongest predictors for severity/overall survival        cytogenetic abnormalities  
• Treatment algorithm for patients performance status  (fig 3.) 
Previous screening  
• Gene therapy is becoming a new reality in different treatments 
• Some interesting results with AAV8-IL24 in MLL/AF4 - Acute Limfoblastic Leukemia cells 
• IL24 induces apoptosis, immunomodulatory and antiangiogenic effects in cancer cells 
New therapies with AAV 
vectors 
• Daurinol: Catalytic inhibitor of hTopoisomerase IIa, similar to etoposide but without 
severe DNA damage 
Alternative drugs 
qPoor hematopoietic reserves make the administration of standard AML therapy difficult because of: 
        Low tolerance for the high toxicity of treatments used 
        Multidrug resistance  phenotype (t-MN emerges during the treatment of previous chemotherapy) 
 
Etoposide 
Mitoxantrone 
Epirubicin 
Some examples 
Figure 2: Model summarizing formation of reciprocal translocation 
breakpoint junctions after treatment of mitoxantrone and epirubicin in 
t-APL 2 
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persistence of mutations 
üHigher DNA damage 
üGreater toxicity  
üReduced survival 
Topoisomerase II is a critical enzyme that relaxes supercoiled DNA by transiently cleaving and religating 
 both strands of the double helix through the formation of a covalent cleavage intermediate 
It is of high priority to gain further knowledge of topoisomerase II inhibitors and their role on therapy – related leukemia  
